a n a ly s i s Large-scale whole-genome sequence data sets offer novel opportunities to identify genetic variation underlying human traits. Here we apply genotype imputation based on wholegenome sequence data from the UK10K and 1000 Genomes Project into 35,981 study participants of European ancestry, followed by association analysis with 20 quantitative cardiometabolic and hematological traits. We describe 17 new associations, including 6 rare (minor allele frequency (MAF) < 1%) or low-frequency (1% < MAF < 5%) variants with platelet count (PLT), red blood cell indices (MCH and MCV) and HDL cholesterol. Applying fine-mapping analysis to 233 known and new loci associated with the 20 traits, we resolve the associations of 59 loci to credible sets of 20 or fewer variants and describe trait enrichments within regions of predicted regulatory function. These findings improve understanding of the allelic architecture of risk factors for cardiometabolic and hematological diseases and provide additional functional insights with the identification of potentially novel biological targets.
Heritable influences on cardiometabolic and hematological traits have been identified across the allele frequency spectrum. Rare (MAF < 1%) and highly penetrant variants with large phenotypic effects have been identified, but these account for a small proportion of phenotypic variance 1, 2 . At the other end of the allelic frequency spectrum, genome-and exome-wide association analyses based on sparse arrays have identified thousands of common (MAF ≥ 5%) and low-frequency (MAF = 1-5%) single-nucleotide variants (SNVs) with modest effects [3] [4] [5] [6] [7] [8] [9] [10] [11] . To investigate the influence of rare, less frequent and common variation on complex traits, we applied whole-genome sequencing in individuals from two UK cohorts, the St Thomas' Twin Registry (TwinsUK) 12 and the Avon Longitudinal Study of Parents and Children (ALSPAC) 13 , as part of the UK10K project. Sequencing was performed at an average depth of 7× across 3,781 individuals. The final data set is described in ref. 14 and consists of 42 million SNVs, 3.5 million indel polymorphisms and nearly 18,000 large deletions.
The initial phase of the UK10K project applied different statistical tests to identify rare alleles associated with a broad range of complex phenotypes. Besides yielding the first examples of new trait associations identified through population-based whole-genome sequencing 15, 16 , the project provided large-scale empirical evaluation of strategies for testing association of variants in the low-frequency and rare ranges. First, the study demonstrated a lack of low-frequency alleles with high penetrance and consequent power for detection (defined by an effect for each variant of >1.2 s.d. and MAF ~0.5%). This confirms expectations that, in this frequency range, new discoveries require larger samples with greater statistical power. Further, the study defined, through simulations and empirical evidence, the allelic space where genotype imputation is expected to be most beneficial for association studies. Finally, it developed a new genotype imputation panel based on whole-genome sequence that enhances imputation accuracy for low-frequency and rare variants in populations of European descent 17 , substantially improving resolution and power in this frequency range.
Capitalizing on these discoveries, we sought to increase the representation of rare variation in association studies of cardiometabolic Discovery and refinement of genetic loci associated with cardiometabolic risk using dense imputation maps Among the seven secondary signals within 1 Mb of a known locus, one was associated with HDL cholesterol levels (an intronic variant of ABCA1), one was associated with uric acid levels (an intronic variant of SLC2A9) and five were associated with hematological indices (PLT, WBC, MCV and MCH). Four loci harbored both common and independent, lower-frequency variants (CCDN3 for MCV; THPO for PLT; GCSAML for PLT; and ABCA1 for HDL cholesterol). The lowfrequency ABCA1 intronic variant rs3824477 (MAF = 0.02) was in strong LD (r 2 = 0.94) with an ABCA1 missense variant (rs2066718, encoding p.Val771Leu) nominally associated with HDL cholesterol (P = 1 × 10 −4 ) in a targeted lipid gene resequencing study 23 .
Three of the ten new loci, and three of the seven secondary signal associations, were observed for low-frequency or rare variants, extending understanding of the genetic architecture of cardiometabolic traits. To illustrate, we considered the effect sizes and allele frequencies of both known and new variants for HDL cholesterol and PLT (Fig. 2a) . Although we identified one rare variant with a large effect size (rs150813342 in GFI1B), the effect sizes of the other new low-frequency variants were similar to those that have been previously reported in genome-wide association studies of common variants. Indeed, for variants with MAF ≥ 0.5%, we had 80% power to detect associations with effect sizes of 0.25, 0.25, 0.35 and 0.55 trait s.d. for HGB, LDL, HOMA-B and IL6, respectively (Fig. 2b) . Although there may be rare variants of large effect that we were unable to identify, we likely did not miss large-effect variants with MAF ≥ 0.5% and sufficient sequencing quality in European populations.
Functional enrichment analysis of trait-associated variants
The majority of the associations we identified were found in noncoding regions, where the underlying molecular mechanisms are poorly defined. To evaluate the functional properties of these variants, we estimated the extent to which associations for each of the 20 traits were non-randomly distributed across various coding, noncoding regulatory and cell-type-specific elements across the genome. We retrieved experimentally derived annotations from 1,005 genomewide data sets from the GENCODE, Encyclopedia of DNA Elements (ENCODE) and Roadmap projects (Supplementary Table 4) . We then used a novel nonparametric approach (GARFIELD) (Supplementary Note) to derive fold enrichment statistics for trait-associated SNPs within each annotation, where SNPs were selected from genome-wide data sets on the basis of their strength of association with each trait   Traits   Lipids  HDL, LDL, TC, TG   Glycemic  FG, FI, HOMA-B, HOMA-IR   Inflammatory/renal  CRP, IL6, uric acid, creatinine   Hematological  HGB, RBC, MCH, MCHC,  MCV, PCV, PLT, 10 new loci 7 new variants at known loci Figure 1 Study design. Summary of traits and studies investigated in this study. Study-specific information is given in supplementary Table 1 . HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; FG, fasting glucose; FI, fasting insulin; HOMA-B, homeostatic model assessment of beta cell function; HOMA-IR, homeostatic model assessment of insulin resistance; CRP, C-reactive protein; IL6, interleukin-6; HGB, hemoglobin; RBC, red blood cell count; MCH, mean cell hemoglobin; MCHC, mean cell hemoglobin concentration; MCV, mean cell volume; PCV, packed cell volume, or hematocrit; PLT, platelet count; WBC, white blood cell count. a n a ly s i s (Online Methods). For an example of results for one trait (PLT) and one annotation type (DNase I hypersensitivity site (DHS) hotspots), see Figure 3 , with all results summarized in Supplementary Figure 2 and Supplementary Table 5 .
Lipid and hematological traits displayed ubiquitous and marked enrichment patterns, with 151 (P < 1 × 10 −8 ) and 906 (P < 1 × 10 −5 ) overall significant fold enrichment statistics for serum lipids and 237 (P < 1 × 10 −8 ) and 749 (P < 1 × 10 −5 ) significant statistics for hematological traits. We found that associations with RBC were enriched in enhancers of the erythroid cell line K562 (fold enrichment = 39.63, empirical P = 2 × 10 −5 ), while associations with WBC were enriched in footprints of CD20 + cells (fold enrichment = 22.16, empirical P < 1 × 10 −5 ). The most significant association for LDL cholesterol was within the transcription start site (TSS) chromatin states measured in the liver HepG2 cell line (fold enrichment = 19.53, empirical P < 1 × 10 −5 ). Conversely, inflammatory and renal traits displayed weak patterns of enrichment. There was significant enrichment of associations (fold enrichment = 4.44, empirical P = 1 × 10 −5 ) with creatinine levels within DHS hotspots of fetal kidney. Uric acid associations were weakly enriched in a small number of liver and fetal intestine annotations. Unexpectedly, we observed enrichment of TG in HMVEC-LLy (lymphatic microvascular endothelial cell) footprints for SNPs with P < 1 × 10 −5 (fold enrichment = 9.75, empirical P < 1 × 10 −5 ), which was much larger than that observed for the broader DHS hotspots (fold enrichment = 4.30, empirical P < 1 × 10 −5 ). By contrast, there was no significant enrichment for footprints of the expected most relevant HepG2 cell type (wellestablished hepatocyte cellular model for cholesterol metabolism).
Fine-mapping of loci using dense imputation from whole-genome sequencing LD and incomplete ascertainment of variants in a region of interest present challenges for pinpointing the causal variant(s) driving an association. To fine-map the causal variant(s) at associated loci, we exploited the high density of our whole-genome sequencing reference panels to define the posterior probability of each variant being causal given all other variants in the region. We selected 417 regions with informative associations (P ≤ 1 × 10 −5 ; Online Methods) in the initial discovery meta-analysis and applied three distinct Bayesian approaches (Maller 24 , FINEMAP 25 and CAVIARBF 26 ) (Online Methods). For each method, we created 95% credible sets by ranking variants on the basis of their decreasing posterior probability (PP) of association. These credible sets contain the minimum list of variants that jointly have at least 95% probability of including the causal variant. We focused on 59 known or new loci where the three methods identified a credible set of fewer than 20 variants and where all variants were either directly genotyped or well imputed (Fig. 4,  Supplementary Fig. 3 and Supplementary Table 6) .
Overall, the 95% credible sets contained an average of 6.9 (s.d. = 5.9) variants per locus when considering the union of all methods, or 5.5 (s.d. = 4.7) variants when considering the intersection. In 45 cases, the three methods yielded identical 95% credible sets, including 13 known and 5 new loci where a single variant was predicted to be causative with PP ~1 by all methods. Of these 18 loci, 5 involved well-characterized missense variants (rs11591147 at PCSK9, rs1260326 at GCKR, rs855791 at TMPRSS6, rs7412 at APOE and rs429358 as a secondary signal at APOE). Missense variants were included in the 95% credible sets at several other loci (ABCG2, APOB, CD300LG, CILP2, HFE, PSORCS1, SH2B3, SLC30A8 and APOH). At four loci, the credible interval included a variant predicted to alter an essential splicing donor or acceptor motif (GCSAML, MLXIPL, BET1L and 
GFI1B-PLT
Index SNP rs150813342 is a synonymous variant altering a predicted GFI1B exon 5 splice site. GFI1B encodes a transcription factor involved in the regulation of red blood cell and platelet production 34 . Rare, heterozygous loss-of-function mutations in GFI1B have been reported in hereditary thrombocytopenia (MIM 187900). rs150813342 has no LD proxies; it is predicted to be causative by CAVIARBF (PP = 1). Furthermore, it lies within a region enriched for H3K4me1 and H3K36me3 in megakaryocytes 52 .
NPRL3-MCH
Index SNP rs117747069 is a low-frequency intronic variant of NPRL3 with no LD proxies. It is predicted to be the most likely causal variant (CAVIARBF PP = 0.84) and is conditionally independent of the common NPRL3 variant rs11248850
previously associated with MCH 8 . NPRL3 is known to contain nucleosome-depleted regions involved in regulation of the α-globin genes on chromosome 16 (ref. 8) . rs117747069 is located in an erythroid-specific super-enhancer [52] [53] [54] [55] , which is hypersensitive, is enriched for H3K27ac marks in erythroblasts and overlaps ChIP-seq signal for the erythroid transcription factors GATA1, GATA2 and TAL1 in K562 cells 56 . Although the nearest gene, NPRL3, is a potential target of the enhancer element, chromatin interactions in K562 cells 56 suggest that the super-enhancer element interacts with several downstream genes, including HBA1 and HBA2.
CCND3-MCV
Index SNP rs112233623 is a low-frequency intronic variant of CCND3, conditionally independent of the previously reported common association of rs9349204 with red blood cell traits 8 . Cyclin D3 has a critical role in cell cycle regulation.
The index SNP is located within an erythroid-specific enhancer 37, 52, 55 enriched for the H3K27ac mark in erythroblasts and is bound by GATA2 and TAL1 in K562 cells 56 . The association of rs112233623 with hemoglobin A2 levels 36 also supports the role of this variant in the regulation of α-globin.
HLA-DRA-WBC
Index variant rs113164910 is a 2-bp indel lying in the class II major histocompatibility complex (MHC) region, 14 kb 3′ of HLA-DRA. The most likely functional SNP, rs9268781 (8 kb 3′ of HLA-DR), is a strong expression quantitative trait locus (eQTL) for various HLA-DR and HLA-DQ genes in blood 57 and overlaps a DHS in blood monocytes 58 . Another LD proxy, rs7763262, has previously been associated with IgA nephropathy 59 .
HLA-B-WBC
Index SNP rs2442735 is located ~20 kb 5′ of the HLA-B locus and is conditionally independent of another HLA-B intronic SNP in the class I MHC region, rs2853946, associated with WBC 60 . The most likely functional SNP, rs2853999, located 1 kb 5′ of HLA-B, is a blood eQTL for HLA-C, C4A and C4B and overlaps a blood cell promoter and enhancer, DHSs and histone marks. A proxy SNP has been associated with marginal zone lymphoma 61 .
THPO-PLT
Index SNP rs78565404 is a second THPO signal, conditionally independent of the previously reported platelet GWAS variant rs6141 (ref. 62 ). Both SNPs fall in the 3′ UTR and have no LD proxies. THPO is a key regulator of platelet production.
THPO gain-of-function mutations have been identified in hereditary thrombocythemia (MIM 187950). rs78565404 binds the transcription factor MAFK (ChIP-seq in HepG2 cells), a component of the NF-E2 complex involved in erythropoiesis and megakaryopoiesis 38, 39 .
GCSAML-PLT
Index SNP rs41315846 is located in a hematopoietic cell lineage-specific promoter of GCSAML (C1orf150) 58 . It is conditionally independent of previously reported GCSAML intronic index SNP rs7550918 and has no LD proxies. GCSAML encodes a protein thought to be a signaling molecule associated with germinal centers, the sites of proliferation and differentiation of mature B lymphocytes. rs41315846 lies within a putative enhancer overlapping a DHS, RUNX1, GATA1
and FLI1 ChIP-seq peaks and an H3K27ac-enriched region in megakaryocytes 52 . that CCNJL is actively expressed in megakaryocytes 52 .
FABP6-PLT
TRABD and MOV10L1-PLT Index SNP rs75570992 is intronic to MOV10L1, a predicted RNA helicase of unknown function. It is predicted to be causal (CAVIARBF PP = 1) and is associated with expression of the neighboring gene TRABD in transformed fibroblasts and colon and lymphoblastoid cells 33, 57 . However, another likely functional SNP is proxy SNP rs75107793 (r 2 = 0.5), which overlaps promoter and enhancer histone marks in many cell types 58 but, more importantly, is located in a putative enhancer overlapping RUNX1 ChIP-seq peaks and a DHS-and H3K4me1-enriched region in megakaryocytes 52 . Functional SNP rs75107793 is also located within a DHS peak in erythroblasts and lies upstream of the TRABD promoter (GENCODE and FANTOM5). On the basis of RNA-seq and epigenetic marks (H3K27ac, H3K4me3 and H3K36me3), TRABD is expressed in megakaryocytes 52 .
ZNF311-WBC
Index SNP rs3130725 is located in an intergenic region on chromosome 6 containing extensive LD (>50 proxy SNPs, r 2 > 0.8), all of which (including rs3130725) are eQTLs in whole blood for several genes in the class I HLA region, including ZFP57, HLA-F and HLA-H 57 . The most likely functional SNP is rs3129794, which is located in the promoter region of ZNF311 and overlaps an active promoter in K562 cells 58 . a n a ly s i s CETP), and at the other three (DNAH11, IKZF1 and GFI1B) the 95% credible set included synonymous sites. For all other loci, the causative set included UTR, intergenic and intronic sites. For each known locus, we compared the variants in the finemapped set with published evidence from functional validation studies (Supplementary Table 6 ). Of the 59 discrete regions, 40 were associated with one trait and 19 were associated with multiple traits. Further, 25 (42%) were known to have at least one causative variant previously functionally validated. At 20 of the 25 loci, the previously validated functional variant was within the 95% credible interval identified using one or more fine-mapping methods. In 11 regions, the known causal variant was ranked with the highest posterior probability by at least one fine-mapping method. We also identified several examples where the credible sets defined high-priority variants for downstream follow-up. Among these are CRP rs1205, a 3′ UTR variant associated with CRP levels that is located in a predicted liver enhancer region that alters a glucocorticoid receptor (NR3C1) transcription factor binding site; rs1822534, a regulatory region variant upstream of PPARG, associated with PLT; ARHGEF3 rs1354034, an intronic variant associated with PLT located in a predicted enhancer region in hematopoietic and primary T cells (Roadmap Epigenomics chromatin state) and predicted to alter a GATA motif; the TC-associated variant rs2169387 located in a predicted liver and muscle enhancer region several hundred kilobases upstream of PPP1R3B; the TC-associated ABCA1 rs2740488 variant located in a liver-specific promoter region; locus-trait Description of most likely functional snP
APOH-PLT
Index SNP rs1801689 (p.Cys325Arg) is located in APOH, which encodes β 2 -GPI, a platelet phospholipid-binding protein.
It is the most likely functional SNP (CAVIARBF PP = 0.37), although another proxy SNP, rs8178824 (r 2 = 1; PP = 0.22), is located in a liver-specific promoter (Roadmap Epigenomics). Platelet promoter capture data (BLUEPRINT) show that rs1801689 physically interacts with neighboring gene PRKCA (protein kinase Cα), which also has a role in platelet function and platelet production in mouse models of megakaryopoiesis 64, 65 .
S1PR3-PLT
Index SNP rs61750929 is located ~100 kb upstream of S1PR3, which encodes a receptor for sphingosine-1-phosphate (S1P) and likely contributes to the regulation of angiogenesis and vascular endothelial cell function 66, 67 . S1PR3 overlaps C9orf47, a gene of unknown function. The index SNP has 33 strong LD proxies in an intergenic region between MIR4289
and S1PR3 (C9orf47), several of which are cis-eQTLs for S1PR3 in whole blood 68 , positioned within megakaryocytic DHSs (rs62549698 and rs9410336) or H3K4me1-enriched enhancer regions (rs9410196, rs142550358 and rs9410336) 52 .
Two proxies in weaker LD (r 2 = 0.5) are synonymous (rs11795137) or 3′ UTR (rs62551536) variants of C9orf47.
RASSF3-PLT
Index SNP rs113373353 and all 33 of its proxies are intronic to RASSF3, a tumor suppressor that also promotes apoptosis.
The most likely functional SNP, rs77164989 (r 2 = 0.8), lies within a putative enhancer that overlaps DHSs, H3K4me1 marks and RUNX1 ChIP-seq peaks in megakaryocytes 52 .
SHROOM3-HCT
Index SNP rs10008637 is intronic to SHROOM3, which encodes a protein that binds and regulates the subcellular distribution of F actin 69 . An intronic LD proxy, rs13146355, located in SHROOM3 is associated with lower serum creatinine 20 and higher serum magnesium 21 levels. Another LD proxy, rs17319721 (r 2 = 0.8), overlaps DHSs in endothelial cells and is located in a TCF7L2-dependent enhancer, increasing SHROOM3 transcription and influencing transforming growth factor (TGF)-β1 signaling and renal function 70 . Box 1 Biological and functional annotation of new genetic variants and loci a n a ly s i s the PLT-associated variant rs12005199 located in a putative enhancer region upstream of AK3 bound by GATA1, GATA2 and TAL1; the PCV-associated HK1 intronic variant rs17476364 located in a hematopoietic cell enhancer region; and the TG-associated variant rs964184 located in a liver and fat enhancer within the ZNF259 3′ UTR.
ABCA1-HDL

Regulatory annotation of locus-specific findings
To inform our statistical fine-mapping approach, for every variant in a credible set we applied two scores for regulatory function based on cell-type-specific DHSs: the deltaSVM score and the Contextual Analysis of Transcription Factor Occupancy (CATO) score (Online Methods) 27, 28 (Supplementary Table 6 ). The functional activity of a variant's effect allele is predicted by the magnitude of the deltaSVM score, with the sign indicating increase or decrease in DNase I hypersensitivity and, therefore, transcription factor binding potential at the site. Similarly, the functional activity of a variant's effect allele is predicted by the CATO score, where scores of 0.1 have a 51% true positive rate for perturbing known transcription factor motifs, with the true positive rate increasing as the score increases to 1 (ref. 28 ).
To identify putatively causal variants, we considered deltaSVM scores greater than 10 in absolute value, CATO scores >0.1 and high posterior probability from the statistical fine-mapping methods. This union-of-methods approach identified several strong cases for causal variants. At the TRIB1 locus associated with the TG, TC and LDL cholesterol traits, rs112875651 had the strongest evidence for causality from all three fine-mapping methods (0.517, 0.532 and 0.526) and from extreme CATO and deltaSVM scores (0.315 and −12.31, respectively Fe tal ren al pe lvis F e ta l re n a l c o rt e x F e ta l p la c e n ta , but these SNPs were four orders of magnitude less significant than rs112875651 in our TG analysis, suggesting that rs112875651 may be a causal variant at TRIB1. At the CELSR2 locus associated with LDL and TC, all three fine-mapping methods provided evidence for causality (0.205, 0.202 and 0.200) of rs12740374, although rs646776 (r 2 > 0.8) was a stronger predicted causal variant from the posterior probability estimates. However, additional evidence for rs12740374 as the causal variant came from a high CATO score (0.199) and an extreme deltaSVM score (14.37) for cell types with significant enrichment predicted by GARFIELD (liver and epithelial cells). The CATO and deltaSVM scores are also helpful when there are no obvious causal candidates from statistical fine-mapping. At the CXCL2 locus associated with WBC, the posterior probabilities did not provide sufficiently strong evidence for a single causal variant. However, index variant rs13128896 had strong functional evidence from its high CATO score (0.146) and its extreme deltaSVM score (−10.71) for blood and skin cell types, with the former cell type being enriched for WBC associations in the GARFIELD analysis.
Integration of methods to prioritize variants for follow-up
We further combined information from fine-mapping analysis, genome-wide functional enrichment results and regulatory scores to assess the overall evidence supporting functional and causal interpretation at 66 independent regions (in 59 loci). There were 17 regions with at least one coding variant, 33 regions with support from both functional enrichment and regulatory scores, 9 regtions with functional scores only, and 6 regions with enrichment only (Fig. 5a) . Variants with functional enrichment overlap and those with regulatory scores had larger posterior probabilities of causality (average PP increase of 0.3 and 0.1, respectively) (Fig. 5b) , in contrast to variants with no such regulatory support, highlighting them as statistically more likely to be causal. For 24 of the 66 regions, we found functional or regulatory support for only a fraction of the variants within credible sets (Fig. 5c) , ranging from 29-94% of variants with annotation from at least one type of evidence (mean = 74%, s.d. = 18%), resulting in up to a 71% reduction of the credible set. There was one fine-mapped region (G6PC2 locus associated with glucose levels) with only statistical and no regulatory support; however, the credible set contained a single causal variant with PP >0.999 from all three fine-mapping approaches, and the variant has previously been shown to enhance G6PC2 pre-mRNA splicing 31 .
DISCUSSION
Our analysis demonstrates the utility of deep imputation from wholegenome sequence reference panels for informing studies of quantitative cardiometabolic and hematological traits. By combining the UK10K and 1000 Genomes Project sequence data, we constructed a dense imputation reference panel that substantially improves upon the HapMap 2 and 1000 Genomes Project panels. With this reference panel, we investigated associations with variants with a frequency as low as 0.5%. Consistent with previous reports 17, 32 , our imputation accuracy declined with decreasing allele frequencies. Therefore, we did not consider very rare variants (MAF ≤ 0.001) or variants with poor imputation quality (INFO ≤ 0.4). This resulted in a substantial culling of the total number of variants that were identified in the UK10K project. Thus, our study may have missed rare variant associations that would be identifiable in a larger study. Because genotype imputation provides model-based estimates of allelic probabilities a n a ly s i s in the study subjects, rather than hard-called, empirically based genotypes, we could not reference cluster plots or intensity files to validate our findings. In this context, independent replication serves a critical function for validating associations from an imputation-based discovery effort. Our dense imputation reference panels expanded the set of variants amenable to association analysis. Only one of the 17 new loci we report was well tagged (r 2 > 0.8) in HapMap 2 or 1000 Genomes Project Phase 1. Markers assessed in previous GWAS of PLT, hemoglobin and WBC poorly tagged nine of the new loci associated with hematological traits. However, for PLT (the trait for which we observed the most and strongest associations), the new loci identified here increased the percentage of phenotypic variance explained from 7.71% to 8.23%. Although increasingly large imputation panels are useful for investigating low-frequency and rare variants, considerably larger sample sizes are needed to identify rare variants of modest-tolarge effect.
For each new locus identified, we undertook epigenomic, tissue expression and fine-mapping analyses to describe the potential mechanism of the association (Box 1). Our results implicate several genes or loci not previously known to be involved in regulation of blood cell counts. For example, the chromosome 22 PLT index variant rs75570992 is located upstream of TRABD, a gene of unknown function. On the basis of RNA-seq and epigenomic data from BLUEPRINT, TRABD is expressed in megakaryocytes. The index variant rs75570992 is associated with differential expression of TRABD in blood cells 33 . The index variant is in partial LD with rs75107793 (r 2 = 0.5), which lies upstream of the TRABD promoter in a putative megakaryocyte enhancer enriched for monomethylation of histone H3 at lysine 4 (H3K4me1) overlapping a ChIP-seq site for the hematopoietic transcription factor RUNX1.
Another newly discovered locus leading to new mechanistic insights is GFI1B rs150813342, a synonymous variant predicted to alter an exonic splicing enhancer. GFI1B is a hematopoietic transcription factor required for normal red blood cell and platelet production 34 . The rs150813342 variant influences the relative amounts of two GFI1B transcript isoforms, a full-length (long) isoform and a short isoform lacking the alternatively spliced exon 5 (ref. 22 ). We further demonstrate the lineage-specific role of the long GFI1B isoform in megakaryocyte development. Previous studies have suggested that the short GFI1B isoform is required for red blood cell production 35 .
We identified several secondary, independent signals in genes previously implicated in regulation of blood cell counts (CCDN3, NLPR3 and THPO). The new MCV-associated CCDN3 low-frequency variant rs112233623 was also associated with hemoglobin A2 levels 36 . rs112233623 is located within an erythroid-specific enhancer 37 and is bound by the hematopoietic transcription factors GATA2 and TAL1. Similarly, NLPR3 rs117747069 is located in an erythroid enhancer element involved in α-globin gene regulation and overlaps GATA2 and TAL1 ChIP-seq sites. A 3′ UTR variant of the thrombopoietin gene (THPO rs6141) was previously associated with higher PLT. We identify a second, independent 3′ UTR THPO signal, rs78565404. By ChIP-seq, rs78565404 is bound in liver HepG2 cells by musculoaponeurotic fibrosarcoma oncogene homolog K (MAFK), a component of the hematopoietic NF-E2 transcription factor complex involved in megakaryopoiesis 38, 39 .
Several of our newly identified variants are located within genes for congenital (GFI1B and THPO) or acquired (APOH) platelet disorders, underscoring the idea that more subtle genetic variation within genes known to contain loss-of-function variants may reflect betweenindividual differences in these complex traits. Rare loss-of-function GFI1B mutations have been identified in patients with congenital thrombocytopenia 40, 41 , while THPO mutations have more often been found in pedigrees with hereditary thrombocytosis. Most of the THPO mutations described in patients with familial thrombocytosis have involved noncoding sequence (splice-site, 5′ UTR and intronic) gain-offunction mutations that lead to enhanced THPO mRNA translation efficiency [42] [43] [44] [45] . It remains to be determined whether the two common 3′ UTR variants of THPO associated with higher PLT similarly enhance mRNA translation and thrombopoietin synthesis. Recently, the first 'loss-of-function' THPO missense mutation (p.Arg38Cys) was associated with aplastic anemia in the homozygous state and mild thrombocytopenia in the heterozygous state 46 .
Apolipoprotein H (APOH) is also known as β 2 glycoprotein I (β 2 -GPI), a major autoantigen for antiphospholipid antibody syndrome (APS), a clinical disorder characterized by arterial and venous thrombosis 47, 48 . Thrombocytopenia is also sometimes a feature of APS. The p.Cys325Gly variant encoded by APOH rs1801689 disrupts the β 2 -GPI phospholipid-binding site 49 APOH/β 2 -GPI is also a component of LDL and binds to members of the LDL receptor family. The same APOH rs1801689 missense variant associated with higher platelet count was recently associated with higher LDL 19 . β2-GPI and antiphospholipid antibody complexes bind to LRP8, an LDL receptor present on platelets and endothelial cells; this interaction has been postulated to have a role in β 2 -GPI-mediated thrombosis 50, 51 . However, even when we controlled for LDL levels, the rs1801689 association with platelet count remained intact, suggesting independent mechanisms driving the associations.
We undertook extensive fine-mapping of previously reported loci, identifying 59 loci where we could reduce associated signals to credible sets of 20 variants or fewer. We observed that the number of variants in the credible set was negatively correlated with the allele frequency of the index SNP, as expected because rare variants have fewer proxies on average. The newly identified loci had lower average MAFs and a lower number of proxies, making the identification of causative variants more straightforward. Rare variants were also more likely to have severe consequences or lead to changes in the protein, facilitating the identification of likely causative genes.
Our enrichment analyses showed that SNPs significantly associated with a phenotype of interest are over-represented within 'functional' regions that were derived in a broad range of cell types and tissues. We evaluated the extent to which genetic associations for each of the 20 traits were enriched in different functional domains and found that lipids and platelet counts were enriched in a large number of tissues and cell types in comparison to other traits displaying more localized (red blood cell traits) or null (renal and inflammatory traits) enrichment patterns. In combination with the fine-mapping experiments, we observed a positive correlation between the posterior probability of causality and overlap with significantly enriched annotations. Overall, this suggests that the process of sifting through putative causal variants can benefit from multiple-pronged approaches incorporating fine-mapping analysis to additional regulatory information obtained from epigenomes and deltaSVM and CATO scores. This information in turn empowers downstream functional experiments by guiding explorations of the functional consequences for sets of associated variants.
By performing detailed epigenomic and functional annotation, we were able to suggest several novel mechanisms for variants at known loci (for example, differential splicing for GFI1B, experimentally demonstrated in ref. 22) or posit strong biological candidates for further functional and cellular study on platelet production (for example, TRABD) and highlight potential genetic connections betweena n a ly s i s platelet count and traditional cardiovascular disease risk factors such as cholesterol levels (APOH). Imputation using dense genotype maps affords a greater understanding of the relative contribution of rare and low-frequency variants to complex traits and allows the finemapping of common variant association signals to manageable credible sets. In parallel, the development of robust functional enrichment methods and the overlap of fine-mapped associations with genome functional maps allowed us to pinpoint variants with high probability of being causal.
URLs. GARFIELD software is available in a standalone version at http://www.ebi.ac.uk/birney-srv/GARFIELD/ and as a Bioconductor package at http://bioconductor.org/packages/release/bioc/html/ garfield.html. DeltaSVM scores were downloaded from http://www. beerlab.org/deltasvm/.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Imputation.
Whole-genome-sequence-based haplotype reference panel. A joint reference panel was created as described in ref. 17 by combining two largescale, low-read-depth whole-genome sequencing data sets, TwinsUK and ALSPAC. The UK10K final-release whole-genome sequencing data for 3,781 samples and 49,826,943 sites were used. From this data set, multiallelic sites, sites containing alleles inconsistent with those from 1000 Genomes Project data and singletons not existing in the 1000 Genomes Project were removed, leaving 28,615,640 sites. SHAPEIT v2 (ref. 75 ) was used to rephase the haplotypes in 3-Mb chunks with flanking regions of ±250 kb. The phased chunks were then recombined with vcf-phased-join from the vcftools package 76 . The 1000 Genomes Project Phase I integrated variant set release (v3) for low-coverage whole genomes in NCBI Build 37 (hg19) coordinates was downloaded from the 1000 Genomes Project FTP site (23 November 2010 data freeze). This call set includes phased haplotypes for 1,092 individuals and 39,293,751 variants (22 autosomes and the X chromosome). For each chromosome, a summary file was generated and merged with that of the UK10K whole-genome sequencing data to identify multiallelic sites and singletons not polymorphic in UK10K. These sites were excluded to create a new set of VCF files. The final reference panel included all 1,092 samples and 32,506,604 sites. The VCF-QUERY tool was used to convert the new VCF files into phased haplotypes and legend files for IMPUTE v2 (ref. 77) .
Prephasing and imputation of target GWAS. Genome-wide SNP data were obtained from each individual study, having undergone study-specific quality control (Supplementary Note). These samples were prephased using SHAPEIT v2, with the mean size of the windows in which conditioning haplotypes were defined set to 0.5 Mb. Because of the significantly higher number of variants in the whole-genome sequencing data, the rephasing was conducted by 3-Mb chunks with 250-kb buffering regions. Phased genotypes were then imputed to one of the three whole-genome sequencing reference panels (UK10K alone, UK10K + 1000 Genomes Project, or 1000 Genomes Project + Genomes of the Netherland (GoNL)) as detailed in Supplementary Table 1. Imputation was carried out using IMPUTE v2 with standard settings 77 .
Association testing. Phenotype preparation. All traits were available from previous studies. Information on trait measurements is summarized in Supplementary Table 1. Traits were transformed by inverse normalization (creatinine, glucose, HDL, HGB, HOMA-B, HOMA-IR, CRP, IL6, insulin, LDL, PCV, PLT, TC, TG and uric acid), square root transform (MCH) or log transform (WBC) or were left untransformed (MCHC, MCV and RBC) to meet the normality assumption for linear model association testing. Traits were further residualized on associated covariables for each trait and each population sample, following detailed information given in the UK10K project paper 14 (summarized in Supplementary Table 4 of ref. 14) . Finally, ten principal components were additionally regressed out from all traits for cohorts with unrelated individuals to further control for potential confounding. Information on individual study characteristics, including trait values and potential additional cohort-specific covariates applied, is given in Supplementary Table 2 and the Supplementary Note. Histograms of trait residuals for which inverse normalization was not applied are shown in Supplementary Figure 4 .
Study design for association testing. The study design is shown in Figure 1 . Briefly, a total of 12,267 to 35,981 participants from 18 different studies were included in the discovery sample. Each cohort carried out single-marker association testing using linear additive models. Genotype dosages were used to account for genotype uncertainty that might arise from sequencing, where each genotype was expressed on a quantitative scale [0:2]. Variants that did not pass a low-frequency threshold (MAF < 0.1%) or were imputed with low accuracy (defined by imputation info score <0.4) were excluded from the analysis. Meta-analyses of cohort summary statistics were performed using GWAMA v 2.1 (ref. 78 ) assuming a fixed-effect model. Genomic control was used to adjust the summary statistics for both input and output data. We prioritized for replication all variants that reached P ≤ 5 × 10 −8 from the meta-analysis of 23 studies. During the course of the study, we updated our meta-analyses several times; variants were prioritized for replication if they met our cutoff (5 × 10 −8 ) during any of these updates. These variants were taken forward into 2,141-102,505 additional independent samples from seven cohorts (Supplementary Table 1) , depending on the trait. Evidence for validation was based on a Bonferroni-corrected stage 2 P value of 8.6 × 10 −4 (0.05/58) and a joint meta-analysis P value of 8.31 × 10 -9 (ref. 14).
Fine-mapping of associated loci (new and previously identified GWAS regions). Annotation and selection of index variants for previously reported loci.
For each trait, we compiled a list of known loci by selecting all index SNPs associated with our traits of interest (lipids, fasting glucose, HOMA, uric acid, CRP, and blood cell counts and indices) from the National Human Genome Research Institute (NHGRI) GWAS catalog (P ≤ 5 × 10 −8 ; last updated in May 2014), supplemented by manual curation of all associations reported in the literature reaching the same genome-wide significance cutoff. Only index variants with marginal significance in the UK10K whole-genome sequencing cohort single-marker association statistics (P ≤ 0.05) were considered for conditional tests. Using TwinsUK and ALSPAC sequence data, we selected variants with P values less than 1 × 10 −3 in the two-way meta-analysis. For each such variant, we extracted regions for fine-mapping on the basis of HapMap estimates of recombination rates. When a region contained multiple correlated index variants associated with a given trait in the GWAS catalog, we clumped the set of index variants to remove ones that were highly correlated (using an LD metric of r 2 > 0.8 applied to a 2-Mb sliding window for each known index SNP (±1 Mb)). This approach avoids collinearity errors when a variant is conditioned against multiple correlated index variants.
LD pruning of UK10K index variants. We next applied an additional LD clumping procedure to thin the list of variants associated with each trait, assigning sets of variants to discrete LD bins if their pairwise r 2 metrics were ≥0.2. For each LD bin, the variant most associated with the trait in question was retained for assessment in conditional analyses. Index variants for previously reported loci that mapped to within ±1 Mb of an index variant for a known locus were also annotated.
Conditional analyses. Sequential conditional single-variant association analyses were carried out to confirm statistical independence of associations. In the initial round of conditional analysis, associations of SNVs with the respective quantitative trait were conditioned on the index variants for known loci clumped (r 2 > 0.8) as described before (this step was carried out only for SNVs within ±1 Mb of a known locus); in further rounds, associations were conditioned against all nearby known loci plus the best new variant identified in the previous round of conditional analysis. The conditional analysis was performed independently for each cohort and a meta-analysis was conducted at the end of each round until the conditional association P value was no longer significant (P > 1 × 10 −5 ). A variant was considered independent if it had conditional P ≤ 1 × 10 −5 (corresponding to r 2 < 0.2 in our data).
Finally, variants were classified as 'known' (denoting either a previously reported GWAS index variant or a variant for which the association signal disappears after conditioning on the known locus) or 'new' (denoted as a variant that is still conditionally independent of known loci and eventual other new independent signals in that region). For new signals, the variant with the lowest conditional P value among multiple associated variants is reported.
Bayesian fine-mapping methods. For each previously reported (known) association and each new index variant, we extracted regions for fine-mapping on the basis of HapMap estimates of recombination rates according to Maller et al. 24 . Specifically, the boundaries were chosen to be at a distance of at least 0.1 cM on either side of the index or known SNP and, if necessary, were extended further to include all tagging variants (r 2 > 0.1 within 1-Mb windows). Of the previously reported loci, only informative associations (P ≤ 1 × 10 −5 in the discovery-stage analysis) were taken forward. Regions with multiple SNPs reported to be associated with the same trait were merged if overlapping. Analysis of each region was then performed separately using three different methods. We implemented the method of Maller et al. 24 , by converting our discoverystage meta-analysis P values to Bayes' factors of association using Wakefield's approximation 79 . Additionally, we employed the fine-mapping methods CAVIARBF 80 and FINEMAP 25 , both Bayesian approaches that use association summary statistics (rather than original genotypic data) and SNP correlations to compute Bayes' factors. The Bayes' factors from each method were then used to calculate posterior probabilities, on the basis of the assumption that there is a single causal SNP in each region. Conditional association analysis on the top fine-mapped variant was additionally carried out and (conditional)
